Physician profile
Patricia Honea Stewart
NPI 1689803918
$214,635.46
in general payments reported to CMS, 2019-2025
26 companies · $68K in 2025
The $68K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $168 · 2021: $1,638 · 2022: $17K · 2023: $45K · 2024: $67K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $127K · Consulting Fee: $24K · Travel and Lodging: $22K · Food and Beverage: $6,521 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $126,588.05 |
| Consulting Fee | $24,088.46 |
| Travel and Lodging | $22,282.10 |
| Food and Beverage | $6,521.40 |
| Education | $128.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $124,440.51 | 2021-2025 | Orladeyo |
| Csl Behring | $36,272.96 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Genentech USA, INC. | $30,992.56 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $15,840.97 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,596.73 | 2019-2025 | Trelegy Ellipta, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $1,568.08 | 2024 | Hyqvia, Eohilia |
| Astrazeneca Pharmaceuticals Lp | $1,111.09 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $494.30 | 2022-2025 | Dupixent |
| Genzyme Corporation | $349.69 | 2019-2025 | |
| Galderma Laboratories, L.P. | $174.05 | 2025 | Nemluvio |
| Ionis Pharmaceuticals, INC. | $129.45 | 2025 | Dawnzera |
| Qol Medical, LLC | $121.52 | 2024-2025 | Sucraid, Sucraid |
| Blueprint Medicines Corporation | $77.84 | 2024 | Ayvakit |
| Biocryst Pharmaceuticals, INC. | $69.79 | 2025 | Orladeyo |
| Grifols USA, LLC | $68.92 | 2024-2025 | Prolastin-C Liquid, Xembify |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $65.77 | 2024-2025 | Ruconest |
| Incyte Corporation | $55.12 | 2023 | Opzelura |
| Amgen INC. | $46.42 | 2024-2025 | Tezspire |
| Pfizer INC. | $29.09 | 2025 | |
| Aimmune Therapeutics, INC. | $24.30 | 2021 | |
| Shire North American Group INC | $23.64 | 2019 | |
| Leo Pharma INC. | $23.07 | 2025 | Anzupgo |
| Insmed, INC. | $16.84 | 2025 | Brinsupri, Arikayce |
| Organon LLC | $14.80 | 2025 | |
| Lilly USA, LLC | $14.42 | 2024 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $13.53 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.